Mark McAllister - Concepedia

Author

Mark McAllister

Also Known As

M McAllister, M. McAllister, M. S McAllister, M.S. McAllister, Mark McAllister, Mark Mcallister, Mark S McAllister, Mark S. McAllister, McAllister, Mark

102

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United Kingdom)GlaxoSmithKline (United Kingdom)AstraZeneca (United Kingdom)Simcyp (United Kingdom)Janssen (Belgium)

About

Mark McAllister is an author at Pfizer (United Kingdom) specializing in medicine, pharmacology, and engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	712
2	Engineering	7	7	132
3	Biochemistry	3	3	102
4	Social Sciences	2	2	334
5	Biology	1	1	14

Mark McAllister

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
A new dynamic in vitro model for the multidimensional study of astrocyte–endothelial cell interactions at the blood–brain barrier Luca Cucullo, Mark McAllister, Kelly Kight, Brain Research Blood–brain BarrierNeurophysiologyBrain-immune InteractionVascular BiologyNeuroscience	2002	171
Mechanisms of glucose transport at the blood–brain barrier: an in vitro study Mark McAllister, Ljiljana Križanac-Bengez, Francesco Macchia, Brain Research Glucose TransportBlood–brain BarrierNeurophysiologyMedicineDiabetes	2001	163
In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration James Butler, Bart Hens, Maria Vertzoni, European Journal of Pharmaceutics and Biopharmaceutics	2018	115
Chemical Dependency Treatment Outcomes of Residents in Anesthesiology: Results of a Survey Gregory B. Collins, Mark McAllister, Mark P. Jensen, Anesthesia & Analgesia	2005	90
IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results Alison Margolskee, Adam S. Darwich, Xavier Pépin, European Journal of Pharmaceutical Sciences Pharmacokinetic ModelingMedicineProcess Analytical TechnologyBiostatisticsSimulation Exercise	2016	66
<i>In Vivo</i> Predictive Dissolution (IPD) and Biopharmaceutical Modeling and Simulation: Future Use of Modern Approaches and Methodologies in a Regulatory Context Hans Lennernäs, Anders Lindahl, A. Van Peer, Molecular Pharmaceutics Biopharmaceutical ModelingGastroenterologyBiomedical EngineeringAnnual Orbito MeetingPhysiologically-based Pharmacokinetic Modeling	2017	56
IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes Adam S. Darwich, Alison Margolskee, Xavier Pépin, European Journal of Pharmaceutical Sciences Systems PharmacologySilico PerformancePharmacokinetic ModelingBiochemistryMedicine	2016	45
IMI – oral biopharmaceutics tools project – evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds Alison Margolskee, Adam S. Darwich, Xavier Pépin, European Journal of Pharmaceutical Sciences Pharmacokinetic ModelingBiochemistryMedicineRational Drug DesignAnalytical Chemistry	2016	42
Developing Clinically Relevant Dissolution Specifications for Oral Drug Products—Industrial and Regulatory Perspectives Mark McAllister, Talia Flanagan, Karin Boon, Pharmaceutics Translational MedicineAcceptable SpecificationsBioequivalenceRegulatory PerspectivesBioanalysis	2019	36
Exploring the enzymatic degradation of poly(glycerol adipate) Sadie M.E. Swainson, Vincenzo Taresco, Amanda K. Pearce, European Journal of Pharmaceutics and Biopharmaceutics EngineeringDepolymerizationBiochemical EngineeringGlycerol AdipatePolymer Chemistry	2019	34

Page 1